Previous 10 | Next 10 |
Gainers: Bit Digital (BTBT) +51%.Infinity Pharmaceuticals (INFI) +46%.NanoVibronix (NAOV) +40%.Tilray (TLRY) +26%.Flora Growth Corp. (FLGC) +25%.Youdao (DAO) +24%.Grove (GRVI) +22%.Zhangmen Education (ZME) +23%.First High-School Education (FHS) +22%.Canaan (CAN) +21%.Losers: Hoegh LNG Partner...
naphtalina/iStock via Getty Images The shares of Infinity Pharmaceuticals ([[INFI]] +46.7%) have surged in morning hours after losing nearly a third on Tuesday in apparent reaction to updated data from two mid-stage studies for the company’s oral immuno-oncology candidate, eganeli...
Gainers: Infinity Pharmaceuticals (INFI) +62%, Grove (GRVI) +26%, Shineco (TYHT) +24%, Tilray TLRY +22%, NeuroMetrix (NURO) +19%.Losers: Dyadic (DYAI) -14%, EyeGate Pharmaceuticals (EYEG) -13%, NanoViricides (NNVC) -13%, Myovant Sciences MYOV&...
Bit Digital (BTBT) +39%.Infinity Pharmaceuticals (INFI) +42%.Support.com (SPRT) +36%.Grove (GRVI) +25%.Taoping (TAOP) +24% on proposing to acquire 51% stake in Zhenjiang TaopingThe9 (NCTY) +13%.China Natural Resources (CHNR) +14%.ATA Creativity (AACG) +14%.TAL Education ( TAL) ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re halfway through the week and still going strong with a look at the biggest pre-market stock movers for Wednesday! Source: Eric Urquhart/Shutterstock.com But don’t get too ...
Gainers: Intrusion (INTZ) +65%.MOGU (MOGU) +40%.Oragenics (OGEN) +32%.BiondVax Pharmaceuticals (BVXV) +29%.Sintx Technologies (SINT) +23%.Dyadic International (DYAI) +21%.EyeGate Pharmaceuticals (EYEG) +19%.U.S. Physical Therapy (USPH) +18%.ObsEva SA (OBSV) +16%.Orbsat (OSAT) +15%.Losers: IRS...
IRSA Propiedades Comerciales (IRCP) -69%.Infinity Pharmaceuticals (INFI) -23% on Q2 earnings release and updates data from bladder and breast cancer trials.TRxADE HEALTH (MEDS) -20% on Q2 earnings release.Bit Digital (BTBT) -17%.Flora Growth (FLGC) -15% to f...
luismmolina/E+ via Getty Images Infinity Pharmaceuticals (INFI) issued data updates from two mid-stage trials for eganelisib, the company’s oral immuno-oncology candidate. 49 patients were enrolled in the MARIO-275 study that was designed to evaluate it as a combination therapy wi...
Infinity Pharmaceuticals (INFI): Q2 GAAP EPS of -$0.13 beats by $0.01.Royalty revenue of $0.51M (+41.7% Y/Y) beats by $0.27MAt June 30, 2021, Infinity had total cash, cash equivalents and available-for-sale securities of $97.3M, compared to $106.8M at March 31, 2021.Financial Outloo...
- New clinical data from MARIO-275 and MARIO-3 suggest that the addition of eganelisib to standard of care regimens provides patient benefit - - Increases seen in overall survival in 2L urothelial cancer (UC) and in progression free survival in 1L triple negative breast cancer...
News, Short Squeeze, Breakout and More Instantly...
Infinity Pharmaceuticals Inc. Company Name:
INFI Stock Symbol:
NASDAQ Market:
Infinity Pharmaceuticals Inc. Website:
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - Infinitum Copper Corp. (TSXV: INFI) (OTCQB: INUMF) (" Infinitum " or the " Company ") is pleased to announce that it has received acceptance from the TSX Venture Exchange (the " Exchange ") of the previously announced consolidation ...
VANCOUVER, BC / ACCESSWIRE / April 3, 2024 / Infinitum Copper Corp. (TSXV:INFI, OTCQB:INUMF) (" Infinitum " or the " Company ") is pleased to announce the details of a proposed consolidation of its common shares. On March 21, 2024, in accordance with the constating documents of the Company, the ...
VANCOUVER, BC / ACCESSWIRE / March 6, 2024 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company "). Further to the Company's news release of March 5, 2024 (the " March 5, 2024 News Release "), this is to advise that the Company has amended the terms of its private pl...